Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CochlearCHEOF +1.61%60 5-Year Yield-on-Cost % is 10.73 as of Jul. 22, 2026, which is 150% above its 10-year median of 4.30. GuruFocus rates CHEOF with a GF Score™ of 60/100 and a GF Value™ of $215.26 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 323 Medical Devices & Instruments companies, Cochlear ranks better than 90.4% on this metric.
Cochlear's yield on cost for the quarter that ended in Dec. 2025 was 10.73.
The historical rank and industry rank for Cochlear's 5-Year Yield-on-Cost % or its related term are showing as below:
CHEOF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.44 Med: 4.3 Max: 13.84
Current: 10.73
During the past 13 years, Cochlear's highest Yield on Cost was 13.84. The lowest was 1.44. And the median was 4.30.
CHEOF's 5-Year Yield-on-Cost % is ranked better than 90.4% of 323
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs CHEOF: 10.73
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Cochlear 5-Year Yield-on-Cost % Related Terms
CHEOF vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Cochlear's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Cochlear's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Cochlear is calculated as
Cochlear (CHEOF) has a 5-Year Yield-on-Cost % of 10.73 as of Jul. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cochlear and its competitors. This is 150% above median its historical median of 4.30. Over the past decade, Cochlear's 5-Year Yield-on-Cost % has ranged from 1.44 to 13.84. According to the industry distribution chart, Cochlear ranks #31 out of 323 companies in the Medical Devices & Instruments industry, placing it in the top 9.6%.
Is Cochlear's 5-Year Yield-on-Cost % too high?
Cochlear's current 5-Year Yield-on-Cost % of 10.73 is 150% above median its 10-year median of 4.30. Over the past 10 years, this metric has ranged from a low of 1.44 to a high of 13.84. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.42. Cochlear's value of 10.73 is 343.4% above this industry median. Based on the distribution chart, Cochlear ranks #31 out of 323 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cochlear has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #31 out of 323 companies for 5-Year Yield-on-Cost %. This places Cochlear in the top 10% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.42. Cochlear's value of 10.73 is 343.4% above this benchmark. Historically, Cochlear's own 5-Year Yield-on-Cost % has ranged from 1.44 to 13.84 over the past decade. While the company's 10-year median is 4.30 vs. the industry median of 2.42, Cochlear has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.42, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cochlear's current 5-Year Yield-on-Cost % of 10.73 is 343.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current 5-Year Yield-on-Cost % is 10.73, which is 150% above median its own 10-year median of 4.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (CHEOF) is currently considered Significantly Undervalued. The stock's GF Value™ is $215.26, compared to a current price of $84.74 — trading 60.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 10.73, which is 150% above median its 10-year median of 4.30 and 343.4% above the Medical Devices & Instruments industry median of 2.42. Cochlear's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cochlear (CHEOF), the current 5-Year Yield-on-Cost % is 10.73 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (CHEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of $84.74 is trading 60.6% below its estimated GF Value™ of $215.26.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for CHEOF:
5-Year Yield-on-Cost %: 10.73 (150% above median its 10-year median of 4.30)
GF Value™: $215.26 vs. price of $84.74 (60.6% below fair value)
Industry Position: 343.4% above the Medical Devices & Instruments median (#31 of 323)
No single metric tells the full story. See the CHEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
60GF Score
Get the complete analysis for CHEOF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHEOF has been successfully added to your 
